EoCene Ltd. is a GI-focused medtech and biopharmaceutical company. It building a diversified platform which combines medical devices, therapeutics and enabling technologies to address significant unmet clinical needs and improve patient outcomes. Its flagship product includes CG-100. EoCene Ltd., formerly known as Galmed Pharmaceuticals, is based in RAMAT-GAN, Israel.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | -- |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-15.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | -- |
| Free Float | 0.84M |
| Market Capitalization | -- |
| Average Volume (Last 20 Days) | -- |
| Beta (Past 60 Months) | -- |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 76.14% |
| Annual Dividend (Based on Last Quarter) | -- |
| Dividend Yield (Based on Last Quarter) | -- |